Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents - PubMed (original) (raw)
Clinical Trial
. 1993 Apr 1;328(13):914-21.
doi: 10.1056/NEJM199304013281303.
Affiliations
- PMID: 8446138
- DOI: 10.1056/NEJM199304013281303
Free article
Clinical Trial
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents
B J Materson et al. N Engl J Med. 1993.
Free article
Erratum in
- Correction: single-drug therapy for hypertension in men.
Materson BJ, Reda DJ. Materson BJ, et al. N Engl J Med. 1994 Jun 9;330(23):1689. doi: 10.1056/NEJM199406093302316. N Engl J Med. 1994. PMID: 8177286 No abstract available.
Abstract
Background: Characteristics such as age and race are often cited as determinants of the response of blood pressure to specific antihypertensive agents, but this clinically important issue has not been examined in sufficiently large trials, involving all standard treatments, to determine the effect of such factors.
Methods: In a randomized, double-blind study at 15 clinics, we assigned 1292 men with diastolic blood pressures of 95 to 109 mm Hg, after a placebo washout period, to receive placebo or one of six drugs: hydrochlorothiazide (12.5 to 50 mg per day), atenolol (25 to 100 mg per day), captopril (25 to 100 mg per day), clonidine (0.2 to 0.6 mg per day), a sustained-release preparation of diltiazem (120 to 360 mg per day), or prazosin (4 to 20 mg per day). The drug doses were titrated to a goal of less than 90 mm Hg for maximal diastolic pressure, and the patients continued to receive therapy for at least one year.
Results: The mean (+/- SD) age of the randomized patients was 59 +/- 10 years, and 48 percent were black. The average blood pressure at base line was 152 +/- 14/99 +/- 3 mm Hg. Diltiazem therapy had the highest rate of success: 59 percent of the treated patients had reached the blood-pressure goal at the end of the titration phase and had a diastolic blood pressure of less than 95 mm Hg at one year. Atenolol was successful by this definition in 51 percent of the patients, clonidine in 50 percent, hydrochlorothiazide in 46 percent, captopril in 42 percent, and prazosin in 42 percent; all these agents were superior to placebo (success rate, 25 percent). Diltiazem ranked first for younger blacks (< 60 years) and older blacks (> or = 60 years), among whom the success rate was 64 percent, captopril for younger whites (success rate, 55 percent), and atenolol for older whites (68 percent). Drug intolerance was more frequent with clonidine (14 percent) and prazosin (12 percent) than with the other drugs.
Conclusions: Among men, race and age have an important effect on the response to single-drug therapy for hypertension. In addition to cost and quality of life, these factors should be considered in the initial choice of a drug.
Comment in
- Single-drug therapy for hypertension in men.
Johnston GD. Johnston GD. N Engl J Med. 1993 Sep 30;329(14):1043-4; author reply 1045. N Engl J Med. 1993. PMID: 8366912 No abstract available. - Single-drug therapy for hypertension in men.
Pettinger WA, Lee HC. Pettinger WA, et al. N Engl J Med. 1993 Sep 30;329(14):1044; author reply 1045. N Engl J Med. 1993. PMID: 8366913 No abstract available. - Antihypertensive therapy--efficacy and quality of life.
Oparil S. Oparil S. N Engl J Med. 1993 Apr 1;328(13):959-61. doi: 10.1056/NEJM199304013281311. N Engl J Med. 1993. PMID: 8446145 No abstract available.
Similar articles
- Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.
Cushman WC, Materson BJ, Williams DW, Reda DJ. Cushman WC, et al. Hypertension. 2001 Oct;38(4):953-7. doi: 10.1161/hy1001.096212. Hypertension. 2001. PMID: 11641316 Clinical Trial. - Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ. Preston RA, et al. JAMA. 1998 Oct 7;280(13):1168-72. doi: 10.1001/jama.280.13.1168. JAMA. 1998. PMID: 9777817 Clinical Trial. - Diltiazem: its place in the antihypertensive armamentarium.
Fagan TC. Fagan TC. J Cardiovasc Pharmacol. 1991;18 Suppl 9:S26-31. J Cardiovasc Pharmacol. 1991. PMID: 1725539 Review. - Selection of initial antihypertensive therapy, regimen design, and goal blood pressure.
Agarwal R. Agarwal R. Cardiol Rev. 2003 Jul-Aug;11(4):197-205. doi: 10.1097/01.CRD.0000081400.80392.3E. Cardiol Rev. 2003. PMID: 12852796 Review. No abstract available.
Cited by
- Salt sensitivity: a review with a focus on non-Hispanic blacks and Hispanics.
Richardson SI, Freedman BI, Ellison DH, Rodriguez CJ. Richardson SI, et al. J Am Soc Hypertens. 2013 Mar-Apr;7(2):170-9. doi: 10.1016/j.jash.2013.01.003. Epub 2013 Feb 19. J Am Soc Hypertens. 2013. PMID: 23428408 Free PMC article. Review. - Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis.
Palla M, Ando T, Androulakis E, Telila T, Briasoulis A. Palla M, et al. J Clin Hypertens (Greenwich). 2017 Apr;19(4):344-350. doi: 10.1111/jch.12867. Epub 2016 Jul 4. J Clin Hypertens (Greenwich). 2017. PMID: 27378313 Free PMC article. Review. - Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?
Payne KA, Esmonde-White S. Payne KA, et al. Curr Hypertens Rep. 2000 Dec;2(6):515-24. doi: 10.1007/s11906-996-0035-6. Curr Hypertens Rep. 2000. PMID: 11062596 Review. - The evolution of renin-angiotensin blockade: angiotensin-converting enzyme inhibitors as the starting point.
Sica DA. Sica DA. Curr Hypertens Rep. 2010 Apr;12(2):67-73. doi: 10.1007/s11906-010-0091-9. Curr Hypertens Rep. 2010. PMID: 20424943 Review. - The impact of race on response to RAAS inhibition.
Wallace TW, Drazner MH. Wallace TW, et al. Curr Heart Fail Rep. 2005 Aug;2(2):72-7. doi: 10.1007/s11897-005-0012-4. Curr Heart Fail Rep. 2005. PMID: 16036054 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical